Neuronetics Amends Credit Agreement and Revenue Covenants
Neuronetics (STIM) amended its credit agreement with Perceptive Credit Holdings, modifying revenue covenants. The amendment requires a $15M prepayment by November 30, 2026, or automatic termination. Analysts rate STIM as Buy with a $6.00 target, while TipRanks' AI rates it Neutral due to financial weaknesses, though recent earnings show improvement.
How this was made
The 30-second read
Why it matters
The amendment signals tighter financial oversight, which could pressure the share price unless the company demonstrates improved cash generation.
Market read
A micro‑cap credit amendment with new covenants is a modest but material corporate action for traders monitoring STIM.
What to watch
Potential for a future refinancing at better rates if cash flow improves; the $15M optional prepayment may be unused.
Background
Neuronetics (STIM) provides FDA‑cleared neurostimulation devices for depression treatment. The company has been trading below $10 with high leverage.
Ticker impact
Neuronetics amended its credit agreement (Amendment No. 6) adding revenue covenants and a $15M optional prepayment clause.
likely downside as investors price in covenant risk and higher leverage concerns
Covenant tightening and optional prepayment requirements signal cash flow pressure for a micro‑cap with negative free cash flow.
Market effects
May raise scrutiny on other small‑cap med‑tech firms with similar credit structures.
Limited to U.S. listed micro‑caps; no broader regional effect.
Minimal; confined to niche neuro‑stimulation market.
Counterpoint
If the company can meet the new covenants, the amendment could improve credit terms and support the stock.
Key entities
- CompanyNeuronetics
U.S. listed neurostimulation device maker (ticker STIM).
- LenderPerceptive Credit Holdings IV, LP
Administrative agent and lender for the credit agreement.

